Use of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Has Doubled
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
A large cross-sectional cohort study investigated the relationship between hearing loss and measures of neurocognition in survivors of childhood cancers.
Adding acetazolamide reduced time to alkalinization, allowing for earlier administration of high-dose methotrexate; however, it did not reduce overall hospital length of stay.
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
Researchers examined causes of avoidable chemotherapy delays as a means of improving the quality of care for outpatients receiving chemotherapy.
Using remote communications technology, a major cancer center was able to manage symptoms in high-risk patients initiating treatment at a regional location.